Unlocking Blood-Brain Barrier Boosts Immunotherapy Efficacy, Lowers ARIA
Roche’s “brain shuttle” antibody, trontinemab, cleared plaque in Phase 1 with little ARIA, highlighting that bypassing vascular amyloid could be the key.
1381 RESULTS
Sort By:
Roche’s “brain shuttle” antibody, trontinemab, cleared plaque in Phase 1 with little ARIA, highlighting that bypassing vascular amyloid could be the key.
Phase 1b results tease that the small molecule PRI-002 might curb cognitive decline. Phase 2 is slated for early 2024.
In early phase trials, therapy lowering tau translation hinted at cognitive benefit, while going after APP lowered its fragments and Aβ peptides.
At trials conference, multiple amyloid immunotherapy programs reported greatest cognitive benefits for people whose tau tangle deposition has only just begun.
Across several studies, black/African Americans and Hispanic or Latino people had lower amyloid positivity rates than whites. Scientists are studying why.
Most participants in AD research studies and trials are non-Hispanic whites. At a conference in St. Louis, scientists discussed strategies to include diverse populations.
At Leiden conference, scientists discussed how shifting cells toward “specialized pro-resolving mediators” could counter inflammation.
A cholesterol metabolite magnifies pathology in a tauopathy mouse. Microglia need cholesterol to rein in amyloid. ApoE4 jams the fat's export from neuron to glia.
We all know oligodendrocytes maintain myelin. According to scientists at the 2nd Symposium on Lipids in Diseases, they need microglia to do it.
At a conference on lipids in the brain, scientists reported how unsaturated fatty acids might worsen or ameliorate the effects of proteinopathies.
Few people with Down's syndrome have cardiovascular risk factors, yet most develop cerebrovascular disease. Will this complicate anti-amyloid immunotherapy?
Swapping allele expression in astrocytes lowered amyloid load, lessened gliosis, and improved memory. This works even after amyloidosis is in full swing.
Scientists at AAIC debated discrepant results, updated a model of the biomarker-efficacy relationship, and debuted the CenTauR scale for tau PET.
At AAIC 2023, scientists tied clinical success to drug exposure, speed of plaque clearance, amyloid negativity.
The newly proposed scheme uses only amyloid and tau for diagnosis and staging. It establishes parallel tracks for fluid or imaging markers, and recognizes a clinical stage zero.